Forschung
Lehre
Lösungen
Anmelden
DE
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
IGH,
CNRS,
IGH, CNRS
Alboukadel Kassambara has not added Biography.
If you are Alboukadel Kassambara and would like to personalize this page please email our Author Liaison for assistance.
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
British journal of cancer Apr, 2018 | Pubmed ID: 29500406
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Clinical epigenetics Oct, 2018 | Pubmed ID: 30285865
Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.
Cancer letters Feb, 2019 | Pubmed ID: 30419344
Univ Montpellier
Michel Jourdan1,
Hugues de Boussac1,
Elena Viziteu1,
Alboukadel Kassambara1,
Jérôme Moreaux1,2,3
1IGH, CNRS, Univ Montpellier,
2Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier,
3UFR de Médecine, Univ Montpellier
Datenschutz
Nutzungsbedingungen
Richtlinien
Kontakt
BIBLIOTHEKS-EMPFEHLUNG
JoVE-Newsletter
JoVE Journal
Methodensammlungen
JoVE Encyclopedia of Experiments
Archiv
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Ressourcen für Lehrende
Autoren
Bibliothekare
Zugang
ÜBER JoVE
Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten